secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001213900-25-054465
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU
--------------------------------------------------------------------------------

- 11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.
- Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.
- Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.
- No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.
- Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/0001213900-25-054465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/ea0245793-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-054465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer